Advertisement

Advertisement
Lymphoma

Golidocitinib in Relapsed or Refractory Peripheral T-Cell Lymphoma

In a phase II trial (JACKPOT8 Part B) reported in The Lancet Oncology, Song et al found that the selective JAK1 tyrosine kinase inhibitor golidocitinib showed...

Lymphoma

MRD Status and Outcomes With Obinutuzumab- and Rituximab-Based Treatment in Follicular Lymphoma

In an analysis from the phase III GALLIUM study reported in the Journal of Clinical Oncology, Pott et al identified measurable residual disease (MRD)...

CNS Cancers

FDA Grants Accelerated Approval to Tovorafenib for Patients With Relapsed or Refractory BRAF-Altered Pediatric Low-Grade Glioma

On April 23, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the type II RAF inhibitor tovorafenib (Ojemda) for patients 6 months of age...


Advertisement
Neuroendocrine Tumors

FDA Approves Lu-177 Dotatate for Pediatric Patients With GEP-NETs

On April 23, the U.S. Food and Drug Administration (FDA) approved lutetium Lu-177 dotatate (Lutathera) for pediatric patients aged 12 years and older...

Breast Cancer

Imaging Drug to Assist in Detection of Cancerous Tissue Following Lumpectomy Approved

Recently, the U.S. Food and Drug Administration (FDA) approved pegulicianine (Lumisight) for adult patients with breast cancer to assist in the intraoperative...

Advertisement
Advertisement




Sponsored Content


Lymphoma

Matthew J. Matasar, MD, on Indolent NHL: New Data on Copanlisib Plus Rituximab

Issues in Oncology

Predictors of Emergency Department Visits After a New Diagnosis of Cancer

In a retrospective cohort study reported in JCO Oncology Practice, Hong et al found that prior frequent emergency department use was the strongest predictor of postdiagnosis emergency department visits among patients with a new diagnosis of cancer. Study Details The study involved data from...

Advertisement

Impact of Genes on Total Number and Type of Nevi

A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer.  “The goal was to investigate the genetic underpinnings of different mole classes, or...

Breast Cancer

Priya Rastogi, MD, on Breast Cancer: Predicting the Benefit of Extended Letrozole Therapy

Kidney Cancer
Immunotherapy

Real-World Survival Outcomes With Various Treatment Regimens for Metastatic Renal Cell Carcinoma

In a real-world retrospective propensity-matched cohort study reported in JAMA Network Open, Chakiryan et al found that both first-line immunotherapy and combined treatment with targeted therapy plus immunotherapy were associated with improved overall survival vs targeted therapy alone in patients...

Issues in Oncology
COVID-19

Organizations Issue Statement Encouraging Return to HPV Vaccination

Doctors and scientists across America at National Cancer Institute (NCI)-designated cancer centers and other organizations recently issued a joint statement urging the nation’s health-care systems, physicians, parents, children, and young adults to get human papillomavirus (HPV) vaccination back on ...

Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma

In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...

Breast Cancer

Linda T. Vahdat, MD, MBA, on Triple-Negative Breast Cancer: Targeting the Tumor Microenvironment

Breast Cancer
Survivorship

Breast Cancer Risk Prediction Model for Childhood Cancer Survivors Who Received Chest Radiation

In an analysis from the Childhood Cancer Survivor Study (CCSS) and the Dutch Hodgkin Late Effects and LATER cohorts reported in the Journal of Clinical Oncology, Moskowitz et al developed a model for predicting the risk of breast cancer among childhood cancer survivors treated with chest...

Advertisement

Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...

Twitter